Nwam LLC Grows Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Nwam LLC boosted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 3.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,473 shares of the biopharmaceutical company’s stock after buying an additional 551 shares during the period. Nwam LLC’s holdings in Bristol-Myers Squibb were worth $1,045,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. NewEdge Wealth LLC grew its stake in Bristol-Myers Squibb by 23.7% in the 4th quarter. NewEdge Wealth LLC now owns 26,443 shares of the biopharmaceutical company’s stock valued at $1,496,000 after buying an additional 5,073 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $82,000. Oregon Public Employees Retirement Fund grew its stake in Bristol-Myers Squibb by 0.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 173,899 shares of the biopharmaceutical company’s stock valued at $9,836,000 after buying an additional 450 shares in the last quarter. Checchi Capital Advisers LLC grew its position in shares of Bristol-Myers Squibb by 6.9% during the 4th quarter. Checchi Capital Advisers LLC now owns 12,038 shares of the biopharmaceutical company’s stock valued at $681,000 after purchasing an additional 774 shares in the last quarter. Finally, Bryn Mawr Capital Management LLC grew its position in shares of Bristol-Myers Squibb by 4.4% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 7,590 shares of the biopharmaceutical company’s stock valued at $429,000 after purchasing an additional 318 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $59.71 on Friday. The company has a 50-day simple moving average of $57.15 and a two-hundred day simple moving average of $54.70. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10. The firm has a market cap of $121.17 billion, a price-to-earnings ratio of -13.51, a PEG ratio of 2.07 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, equities analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 4.15%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently -56.11%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on BMY shares. Leerink Partners upgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Bank of America restated a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Wells Fargo & Company boosted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. Cantor Fitzgerald boosted their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Finally, Wolfe Research started coverage on shares of Bristol-Myers Squibb in a research report on Friday, November 15th. They set a “peer perform” rating for the company. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $57.86.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 1,823 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was bought at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 0.09% of the stock is currently owned by company insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.